Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ACADIA Pharmaceuticals Inc

+ Add to Watchlist

ACAD:US

39.9777 USD 0.8423 2.06%

As of 14:22:14 ET on 05/28/2015.

Snapshot for ACADIA Pharmaceuticals Inc (ACAD)

Open: 40.6700 Day's Range: 39.5500 - 40.7900 Volume: 608,714
Previous Close: 40.8200 52wk Range: 19.2100 - 46.4800 1-Yr Rtn: +90.82%

Stock Chart for ACAD

No chart data available.
  • ACAD:US 39.9800
  • 1D
  • 1M
  • 1Y
40.8200
Interactive ACAD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ACAD

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.1500
Est. EPS (USD) (12/2015) -1.2940
Est. PEG Ratio -
Market Cap (M USD) 4,053.02
Shares Outstanding (M) 100.30
30 Day Average Volume 1,314,434
Price/Book (mrq) 14.0419
Price/Sale (ttm) 42,284.6869
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ACAD

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ACAD

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

Stephen R Davis "Steve"Interim CEO/Exec VP/CFOTerrence O MooreExec VP/Chief Commercial Officer
Roger M MillsExec VP:Dev/Chief Medical OfcrGlenn F BaityVP/Secy/General Counsel
More Company Profile & Key Executives for ACAD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil